Articles tagged with: Endometrial

Switching on survival signalling to drive drug resistance

Posted in General News, Publications Published by Bethan Warman 27 February 2018

Resistance to receptor tyrosine kinase-targeted therapies

Switching on survival signalling to drive drug resistance

Researchers at the Barts Cancer Institute (BCI), Queen Mary University of London, led by Dr Richard Grose, Centre for Tumour Biology, have discovered that the loss of a single protein- PHLDA1- is sufficient for the development of drug resistance to a type of targeted therapy in endometrial and HER2-positive breast cancer cells.

Drugs that target specific pathways in cancer cells- so called targeted therapies- offer promising clinical benefits for cancer patients, with less severe side effects compared with more conventional chemotherapy agents. However, drug resistance- whereby cancer cells find ways to evade the effects of these drugs over time- limits the long-term clinical efficacy of these treatments.

This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.